| A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC (NCT07720193) | Nanjing Leads Biolabs Co.,Ltd | 2026-08-22 |
| A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] (NCT07390383) | Nanjing Leads Biolabs Co.,Ltd | 2026-04-13 |
| A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] (NCT07331155) | Nanjing Leads Biolabs Co.,Ltd | 2026-02-26 |
| A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer (NCT07281976) | Nanjing Leads Biolabs Co.,Ltd | 2026-01-27 |
| A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus (NCT07323173) | Nanjing Leads Biolabs Co.,Ltd | 2025-12-16 |
| A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer (NCT07042802) | Nanjing Leads Biolabs Co.,Ltd | 2025-12-02 |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] (NCT07111546) | Nanjing Leads Biolabs Co.,Ltd | 2025-10-20 |
| A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma (NCT07099430) | Nanjing Leads Biolabs Co.,Ltd | 2025-09-05 |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] (NCT06783647) | Nanjing Leads Biolabs Co.,Ltd | 2025-06-11 |
| A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma (NCT06157827) | Nanjing Leads Biolabs Co.,Ltd | 2023-12-08 |
| A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma (NCT06049290) | Nanjing Leads Biolabs Co.,Ltd | 2023-10-20 |
| A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors (NCT05779163) | Nanjing Leads Biolabs Co.,Ltd | 2023-04-14 |
| A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors (NCT05516914) | Nanjing Leads Biolabs Co.,Ltd | 2022-09-01 |
| Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors (NCT05223231) | Nanjing Leads Biolabs Co.,Ltd | 2022-04-19 |
| A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors (NCT05170958) | Nanjing Leads Biolabs Co.,Ltd | 2022-01-06 |
| Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies (NCT05042908) | Nanjing Leads Biolabs Co.,Ltd | 2021-12-02 |
| A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors (NCT05102006) | Nanjing Leads Biolabs Co.,Ltd | 2021-11-30 |
| Phase I/II Clinical Trial of LBL-015 for Injection (NCT05107011) | Nanjing Leads Biolabs Co.,Ltd | 2021-11-08 |
| A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (NCT04640545) | Nanjing Leads Biolabs Co.,Ltd | 2020-05-12 |